Takara Bio Management

Management Kriterienprüfungen 2/4

Takara Bio's CEO ist Koichi Nakao , ernannt in May 2009, hat eine Amtszeit von 15.08 Jahren. besitzt direkt 0.06% der Aktien des Unternehmens, im Wert von ¥73.96M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 5.5 Jahre.

Wichtige Informationen

Koichi Nakao

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	15.1yrs
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Koichi Nakao (62 yo)

15.1yrs

Amtszeit

Mr. Koichi Nakao was Director & President of Takara Bio Inc. from May 2009 to April 2020. Mr. Nakao was Director of Takara Bio Inc. from April 2002 to May 2009. Mr. Koichi Nakao is CEO, President & Represe...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Koichi Nakao	CEO, President & Representative Director	15.1yrs	keine Daten	0.060% ¥ 75.6m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	2.4yrs	keine Daten	0.014% ¥ 17.8m
Tsuyoshi Miyamura	Senior Managing Director & Director	10yrs	keine Daten	0.010% ¥ 12.6m
Junichi Mineno	VP, Executive Officer & Director	2.4yrs	keine Daten	0.012% ¥ 15.2m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	7yrs	keine Daten	0.0025% ¥ 3.2m
Andrew Farmer	Head of Research and Development	no data	keine Daten	keine Daten
Akira Kodera	Managing Executive Officer	1.4yrs	keine Daten	keine Daten
Kyoko Nakajima	Managing Executive Officer	1.4yrs	keine Daten	keine Daten
Nukaya Ikuei	Executive Officer	less than a year	keine Daten	keine Daten
Ikuei Nukaya	Managing Executive Officer	less than a year	keine Daten	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrenes Management: 4974Das Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Koichi Nakao	CEO, President & Representative Director	22.2yrs	keine Daten	0.060% ¥ 75.6m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	3yrs	keine Daten	0.014% ¥ 17.8m
Tsuyoshi Miyamura	Senior Managing Director & Director	6yrs	keine Daten	0.010% ¥ 12.6m
Junichi Mineno	VP, Executive Officer & Director	10yrs	keine Daten	0.012% ¥ 15.2m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	1.4yrs	keine Daten	0.0025% ¥ 3.2m
Mutsumi Kimura	Director	2yrs	keine Daten	0.042% ¥ 53.2m
Masahide Tamaki	Full-Time Auditor	5yrs	keine Daten	0.0050% ¥ 6.3m
Kazuko Kimura	Independent External Director	5yrs	keine Daten	keine Daten
Akihiko Kita	Full-Time Auditor	8yrs	keine Daten	0.0013% ¥ 1.7m
Nobuko Kawashima	Independent External Director	8yrs	keine Daten	keine Daten
Yasuo Himeiwa	External Auditor	8yrs	keine Daten	keine Daten
Noriomi Matsumura	Independent External Director	4yrs	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: 4974Die Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).

Takara Bio Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Less than half of directors are independent

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Consensus EPS estimates fall by 30%

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024

Consensus EPS estimates fall by 56%

Price target decreased by 17% to JP¥1,600

Upcoming dividend of JP¥17.00 per share

Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD)

Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 29%, revenue downgraded

Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 15%

Price target decreased by 17% to JP¥1,933

Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023

Takara Bio Inc. to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥42.00 per share at 2.3% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023

Price target decreased to JP¥2,250

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥2,400

Takara Bio Inc. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥2,515

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Takara Bio Inc. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥30.00 per share

Consensus revenue estimates increase by 16%

Price target decreased to JP¥2,742

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥2,792

Price target decreased to JP¥3,012

Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021)

Consensus EPS estimates increase to JP¥91.00

First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021)

Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Takara Bio Inc. to Report Fiscal Year 2021 Results on May 13, 2021

Analysts increase EPS estimates to JP¥53.65

Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020)

New 90-day high: JP¥3,045

New 90-day low: JP¥2,752

Takara Bio Inc. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: JP¥3,020

Takara Bio Inc. to Report Q2, 2021 Results on Nov 10, 2020

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder